Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964653 | 0.79 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL30216043 | 0.79 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL13488 | 0.77 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL12476315 | 0.75 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL12228594 | 0.75 | TSHR (0.36) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL404991 | 0.75 | TDP1 (0.36) | ALDH1A1 | |
| SCHEMBL579650 | 0.75 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL20870374 | 0.75 | KDM1A (0.35) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL29888885 | 0.75 | KDM1A (0.35) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL16172269 | 0.75 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024005516-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2024-01-04 | — | — | WO | disclosed |
| WO-2024005516-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2024-01-04 | — | — | WO | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| EP-3116862-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3116862-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138220-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015135091-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | WO | disclosed |
| EP-1654269-B1 | NOVEL COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-7521430-B2 | N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070060545-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1654269-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012321-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060545-A1 | Novel compounds | CYP1B1, CYP2B6, CYP4B1 | ALDH1A1 627/4885CA12 1387/4885CA1 1220/4885 |
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | PREP, CTSZ, PEPD | ALDH1A1 955/4885CA12 4777/4885CA1 4713/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | ALDH1A1 2933/4885CA12 3463/4885CA1 1619/4885 |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | PREP, CTSZ, PEPD | ALDH1A1 955/4885CA12 4777/4885CA1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.